Method for preparing endodermal stem cells and islands derived therefrom

JP2026517532APending Publication Date: 2026-06-02エンドセル·セラピューティクス·インコーポレーテッド
View PDF 5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
エンドセル·セラピューティクス·インコーポレーテッド
Filing Date
2025-02-07
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

The clinical application of human pluripotent stem cell (hPSC)-derived cells is hindered by their complex differentiation process and the risk of undifferentiated cells forming teratomas, limiting their use in laboratory research and cell-based therapies, particularly for treating diseases associated with pancreatic islet dysfunction such as diabetes.

Method used

A method involving specific culture steps with Nodal signaling agonists, WNT signaling agonists, fibroblast growth factors, TGF-β superfamily members, and other growth factors to produce high-purity endodermal stem cells and pancreatic endocrine cells, followed by administration of these cells to treat islet dysfunction.

Benefits of technology

The method produces high-purity endodermal stem cells and pancreatic endocrine cells that can safely and effectively treat islet-related diseases by reversing hyperglycemia and improving insulin secretion, with reduced teratoma formation risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026517532000001
    Figure 2026517532000001
  • Figure 2026517532000002
    Figure 2026517532000002
  • Figure 2026517532000003
    Figure 2026517532000003
Patent Text Reader

Abstract

This disclosure provides methods for generating populations of endodermal stem cells (EnSCs), populations of EnSC-derived PP cells, populations of EnSC-derived EP cells, or E islets. This disclosure also relates to EnSCs, EnSC-derived PP cells, EnSC-derived EP cells, or E islets obtained using these methods, and their therapeutic uses.
Need to check novelty before this filing date? Find Prior Art